Table of Content


COMPANY EXECUTIVE SUMMARY 1
Table of Contents 2
Tables 7
Charts 8
Bristol-Myers Squibb Company - Key Company Facts 9
Bristol-Myers Squibb Company - Company Description 10
Bristol-Myers Squibb Company - Top Executives 11
Bristol-Myers Squibb Company- Top Executives Biographies 12
Bristol-Myers Squibb Company- Head Office & Locations 15
Head Office - Country 15
Key Subsidiaries 16
Key Joint Ventures 18
Bristol-Myers Squibb Company - Products and Services 19
Products 19
Bristol-Myers Squibb Company - Historic Events 20
Bristol-Myers Squibb Company – Company’s Management Discussion 22
Bristol-Myers Squibb Company – Company’s Mission and Vision 24
Mission 24
Vision 24
Bristol-Myers Squibb Company - Corporate Strategy 25
Bristol-Myers Squibb Company - Business Description 29
Pharmaceuticals 30
Oncology 30
Immunology 31
Cardiovascular 31
Neuroscience 31
Bristol-Myers Squibb Company - ESG Spotlight 33
Environment 34
Social 35
Corporate Governance 36
Bristol-Myers Squibb Company - SWOT Analysis 37
Overview 37
Strengths 39
Weaknesses 42
Opportunities 44
Threats 46
Bristol-Myers Squibb Company – PESTLE Analysis 48
Overview 48
Political Factors 50
Economic Factors 51
Social Factors 52
Technological Factors 53
Legal Factors 55
Environmental Factors 56
Bristol-Myers Squibb Company - Financial Deep Dive 57
Share Price Trend - Oct-2023to Oct-2024 (Average Share Closing Price) 57
Profit and Loss Statement 59
Summary of Profit and Loss Statement 59
Key Financial Ratio Analysis 61
Bristol-Myers Squibb Company - Ratio Charts 62
Activity Ratio Charts 62
Growth Ratios Charts 63
Leverage Ratio Charts 64
Liquidity Ratio Charts 64
Profitability Ratio Charts 66
Competing Players 67
Snapshot of Competing Players 68
AbbVie Inc 68
Key Company Facts 68
Company Description 68
Snapshot of Competing Players 70
AstraZeneca Plc 70
Key Company Facts 70
Company Description 70
Snapshot of Competing Players 72
Novo Nordisk A/S 72
Key Company Facts 72
Company Description 72
Snapshot of Competing Players 74
Pfizer Inc. 74
Key Company Facts 74
Company Description 74
Snapshot of Competing Players 76
Sanofi SA 76
Key Company Facts 76
Company Description 76
Bristol-Myers Squibb Company - In the News 78
27-Sep-2024- Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting 78
26-Sep-2024- U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY? (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults 80
26-Sep-2024- Bristol Myers Squibb Statement on Oncologic Drugs Advisory Committee (ODAC) Meeting Regarding Class Evaluation of PD-L1 Expression Levels for Immune Checkpoint Inhibitors in Gastric and Esophageal Cancers 82
25-Sep-2024- Bristol Myers Squibb and 2seventy bio Provide Update on KarMMa-9 Trial of Abecma in Patients with Newly Diagnosed Multiple Myeloma 84
18-Sep-2024- New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis 85
18-Sep-2024- New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis 87
15-Sep-2024- Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo? plus Yervoy? in Advanced Melanoma 89
12-Sep-2024- Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024 91
10-Sep-2024- Bristol Myers Squibb Announces Dividend 91
09-Sep-2024- Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms 91
28-Aug-2023- U.S. FDA Approves Bristol Myers Squibb’s Reblozyl? (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions 94
14-Aug-2023- Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day 97
10-Aug-2023- Bristol Myers Squibb Enters Into $4 Billion Aggregate Accelerated Share Repurchase Agreements 100
12-Jul-2023- Bristol Myers Squibb Launches Supporting You with UC, with Women’s World Cup Commentator, Former Professional Soccer Player and Ulcerative Colitis Patient, Rosie White 100
17-Jun-2023- Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma in TRANSCEND Clinical Trials Presented at ICML 2023 102
01-Jun-2023- Bristol Myers Squibb to Participate in Upcoming Investor Conferences 104
26-May-2023- Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expre... 105
03-May-2023- Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy 107

31-Mar-2023- Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy 109
27-Feb-2023- Bristol Myers Squibb to Present Data Supporting its Cardiovascular Portfolio at the American College of Cardiology Annual Scientific Session Together With World Congress of Cardiology 110
Bristol-Myers Squibb Company- Key Deals 111
12-Sep-2023 - BMS Group acquires two Canadian brokers 111
18-Jul-2023 - BMS Re acquires Brazil-based reinsurance broker KNW 112
02-May-2023 - BMS Group acquires Australian MGA - Deal allows BMS to diversify its international operations 113
27-Apr-2023 - Bristol Myers Squibb acquires US viral vector production facility from Novartis 114
17-Aug-2022 - Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio 114
15-Jan-2019 - BMS/Celgene deal will create haematology powerhouse 117
03-Jan-2019 - Bristol-Myers Squibb’s $74 billion acquisition of Celgene would combine two troubled companies 117
05-Nov-2015 - Cardioxyl Sells to Bristol-Myers Squibb for up to $2 Billion 120
Appendix 121
Definitions 121
SWOT Analysis 121
PESTLE Analysis 121
Value Chain Analysis 121
ESG Spotlight 121
Financial Deep Dive 121
Financial Ratios - 122
Activity Ratios 122
Growth Ratios 123
Leverage Ratios 124
Liquidity Ratios 125
Market Ratios 126
Profitability Ratios 126
Research Methodology 127
Disclaimer 128
Contact Us 128



List of Figures

Charts
Figure 1: Bristol-Myers Squibb Company- SWOT Analysis 38
Figure 2: Bristol-Myers Squibb Company - PESTLE Analysis 49
Figure 3: Bristol-Myers Squibb Company - Average Share Price Trend - Oct-2023 to Oct-2024 58
Figure 4: Bristol-Myers Squibb Company - Profit and Loss Statement - 2020-2023 60
Figure 5: Bristol-Myers Squibb Company - Activity Ratio Charts 62
Figure 6: Bristol-Myers Squibb Company - Growth Ratio Charts (Value %) 63
Figure 7: Bristol-Myers Squibb Company - Leverage Ratio Charts 64
Figure 8: Bristol-Myers Squibb Company - Liquidity Ratio Charts 65
Figure 9: Bristol-Myers Squibb Company - Profitability Ratio Charts (Value %) 66
Figure 10: Competing Players - AbbVie Inc - Key Financials 69
Figure 11: Competing Players - AstraZeneca Plc - Key Financials 71
Figure 12: Competing Players - Novo Nordisk A/S - Key Financials 73
Figure 13: Competing Players - Pfizer Inc. - Key Financials 75
Figure 14: Competing Players - Sanofi SA - Key Financials 77

List of Tables

Tables
Table 1: Bristol-Myers Squibb Company - Company Facts
Table 2: Bristol-Myers Squibb Company - Top Executives
Table 3: Bristol-Myers Squibb Company - Top Executives Biographies
Table 4: Bristol-Myers Squibb Company - Subsidiaries
Table 5: Bristol-Myers Squibb Company - Key Joint Ventures
Table 6: Bristol-Myers Squibb Company - Products
Table 7: Bristol-Myers Squibb Company - Historic Events
Table 8: Bristol-Myers Squibb Company - Share Price Trend - Oct-2023 to Oct-2024
Table 9: Bristol-Myers Squibb Company- Ratio Analysis - 2019-2022
Table 10: Bristol-Myers Squibb Company -Competing Players